<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314076</url>
  </required_header>
  <id_info>
    <org_study_id>#19-1590</org_study_id>
    <nct_id>NCT04314076</nct_id>
  </id_info>
  <brief_title>Rhythmic Auditory Stimulation &amp; Gait Training</brief_title>
  <official_title>A Pilot Single-blind Randomized Controlled Trial to Evaluate the Safety and Feasibility of Rhythmic Auditory Stimulation for Gait Training in Persons With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Consortium of Multiple Sclerosis Centers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MedRhythms, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will enroll patients with Multiple Sclerosis and some difficulty with walking. The&#xD;
      purpose of this study is to use Rhythmic Auditory Stimulation (RAS) a music therapy technique&#xD;
      that provides rhythmic auditory cues (like a beat) to help improve a patient's movements,&#xD;
      especially when walking.&#xD;
&#xD;
      Participants will be asked to participate in a walking program (WP) with Rhythmic Auditory&#xD;
      Stimulation (RAS), or a WP without RAS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic&#xD;
      auditory cues (like a beat) to help improve patients' movements, especially when walking. The&#xD;
      RAS can be delivered at a fixed tempo or interactive tempo.&#xD;
&#xD;
      The device used in this study will deliver an interactive tempo. The equipment will include a&#xD;
      mobile device app and sensors that are attached to the participant's shoes. Headphones and&#xD;
      smartphones will be required to use the device and will be provided to the study team and&#xD;
      kept at the center for this study. The device is designed to use audio cues to facilitate&#xD;
      improvements in the participant's walking speed while listening to music.&#xD;
&#xD;
      The overall purpose of this study is to assess the safety and acceptability of interactive&#xD;
      RAS music combined with gait training in individuals with MS and walking impairment, and to&#xD;
      gather preliminary efficacy data for future studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a single blind parallel-group pilot randomized controlled trial comparing rhythmic auditory stimulation (RAS) with gait training to gait training without RAS.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>A blinded examiner will be used to perform the gait analysis, 6 minute walk , and timed 25 foot walk</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>through study completion, up to 16 weeks</time_frame>
    <description>Adverse events will be collected throughout the study period to assess treatment safety.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of training sessions missed.</measure>
    <time_frame>through end of treatment, up to 9 weeks</time_frame>
    <description>Training session attendance will be tracked as an indicator of feasibility throughout the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timed 25 Foot Walk</measure>
    <time_frame>Week 0, Week 9 and week 16</time_frame>
    <description>Participants are instructed to walk as fast as possible but safely on a 25-foot straight course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk</measure>
    <time_frame>Week 0, Week 9 and week 16</time_frame>
    <description>Participants are instructed to walk for 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spatiotemporal gait parameters</measure>
    <time_frame>Week 0, Week 9 and week 16</time_frame>
    <description>Gait parameters at self-selected pace will be collected on an electronic walkway.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MS Walking Scale - 12</measure>
    <time_frame>Week 0, Week 9 and week 16</time_frame>
    <description>The MSWS-12 consists of 12 items inquiring about the impact of MS on various aspects of walking. Score range is from 0 to 100, with higher scores indicating a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Gait Disorders, Neurologic</condition>
  <arm_group>
    <arm_group_label>Gait Training (GT) with Rythmic Auditory Stimulation (RAS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes,with RAS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gait training (GT) without Rythmic Auditory Stimulation (RAS)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in this arm will complete 16 supervised gait training sessions consisting of continuous overground walking on a track for 30 minutes without RAS</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rythmic auditory stimulation</intervention_name>
    <description>RAS, a Neurologic Music Therapy technique developed to utilize rhythm and timing cues to assist in improving the basic, intrinsic rhythmic movements of gait.</description>
    <arm_group_label>Gait Training (GT) with Rythmic Auditory Stimulation (RAS)</arm_group_label>
    <other_name>RAS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gait Training</intervention_name>
    <description>Continuous overground walking on a track for 30 minutes. Gait training will primarily consist of walking exercise under the supervision of an exercise physiologist.</description>
    <arm_group_label>Gait training (GT) without Rythmic Auditory Stimulation (RAS)</arm_group_label>
    <other_name>GT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of MS based on 2017 revised McDonald criteria (relapsing or progressive&#xD;
             course)&#xD;
&#xD;
          -  Performs the T25FW in 8 to 30 seconds (cane(s), walking stick(s), crutch(es), or&#xD;
             wheeled walker allowed)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Physical therapy in the past 3 months or immediate need for PT due to safety concerns&#xD;
             (e.g. falls)&#xD;
&#xD;
          -  Requires at least one seated rest during the 6 MW test&#xD;
&#xD;
          -  Treatment with high-dose corticosteroids in the past 2 months or planned during the&#xD;
             study period&#xD;
&#xD;
          -  Lower extremity botulinum toxin (BT) injections for spasticity in the past 3 months,&#xD;
             or planned during the study period&#xD;
&#xD;
          -  Initiation of an oral symptomatic therapy which could affect walking in the past 4&#xD;
             weeks (particularly dalfampridine and medications for spasticity)&#xD;
&#xD;
          -  Initiation of a new disease-modifying therapy for MS in the past 3 months&#xD;
&#xD;
          -  Comorbidity compromising safe participation or affecting walking (e.g. uncontrolled&#xD;
             cardiac or respiratory illness, musculoskeletal disorder)&#xD;
&#xD;
          -  Severe hearing impairment with or without the use of hearing aids, such that the&#xD;
             participant cannot hear the rhythmic music stimulus consistently.&#xD;
&#xD;
        Inability to walk safely to the rhythmic music stimulus during the baseline visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Bethoux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexis K Skolaris, BS</last_name>
    <phone>216-445-4125</phone>
    <email>skolara@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Miniard, MEd,LPC</last_name>
    <phone>216-386-1153</phone>
    <email>miniara@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Skolaris, BS</last_name>
      <phone>216-445-4125</phone>
      <email>skolara@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Francois A Bethoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jay Alberts, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Gallagher, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Francois Bethoux, MD</investigator_full_name>
    <investigator_title>Chairman, Department of PM&amp;R,</investigator_title>
  </responsible_party>
  <keyword>Gait analysis</keyword>
  <keyword>Music therapy</keyword>
  <keyword>Multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Gait Disorders, Neurologic</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

